- Steady as she goes, milestones recognised and passed
- Cash position, very strong and spending frugal and highly targeted
- no need to approach the market, if institutions want script, then buy on market
- Stage 2 ....results very promising
- stage 3 enrolling...............the rubber hits the road with Specificity, Sensitivity figures
- Gen 2 arising
- Focus on the FDA around the skeleton of the final submission
- Market 2025..........................and then......................
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.74 |
Change
0.000(0.00%) |
Mkt cap ! $148.3M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.74 | $1.74 | $2.545K | 1.467K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5397 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 1309 | 2 |
View Market Depth
| Last trade - 09.59am 23/07/2025 (20 minute delay) ? |
| EMV (ASX) Chart |